Threebrooks Therapeutics Inc - FuturePlay Portfolio Company Details

The company is developing an oral treatment for Parkinson’s disease that activates TRPML1, a lysosomal ion channel. As impaired autophagy resulting from lysosomal dysfunction is increasingly recognized as a key pathological mechanism of Parkinson’s disease, TRPML1 activation is considered a promising approach that directly targets this mechanism. Starting with Parkinson’s disease, the company aims to expand its therapeutic indications to other neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). CEO Sungyoung Kim was the original developer of Aneratrigine, a pain drug candidate developed by Daewoong Pharmaceutical and iN Therapeutics, which was licensed to Niroda Therapeutics in a deal valued at up to USD 500 million. Leveraging this experience, the company is currently exploring business development collaborations with multiple global pharmaceutical companies. The market for neurodegenerative disease treatments is expected to continue growing as the global population ages, and the company aims to establish a competitive position in this market on a global scale.